Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Tesetaxel|DRUG: Tesetaxel|DRUG: Tesetaxel|DRUG: Nivolumab|DRUG: Pembrolizumab|DRUG: Atezolizumab|DRUG: Tesetaxel
Sponsor: Odonate Therapeutics, Inc.